Clinical Trial Update: Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing febuxostat to allopurinol in patients with MAFLD-related hepatic steatosis and hyperuricemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Allopurinol (Allopurinol)
• FEBUXOSTAT (Febuxostat)

Snippet

Sponsor: Ain Shams University | Conditions: Non-Alcoholic Fatty Liver Disease, Hyperuricemia | Phase 4 | Status: COMPLETED